Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer.

Samec, Timothy; Alatise, Kharimat Lora; Boulos, Jessica; Gilmore, Serena; Hazelton, Anthony; Coffin, Carleigh; Alexander-Bryant, Angela

Samec, Timothy; Alatise, Kharimat Lora; Boulos, Jessica; Gilmore, Serena; Hazelton, Anthony; Coffin, Carleigh; Alexander-Bryant, Angela.

Afiliação

Samec T; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Alatise KL; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Boulos J; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Gilmore S; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Hazelton A; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Coffin C; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.
Alexander-Bryant A; Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, 301 Rhodes Research Center, Clemson, SC 29634-0905, USA.

Mol Ther Nucleic Acids ; 30: 95-111, 2022 Dec 13.

Article em En | MEDLINE | ID: mdl-36213692

Palavras-chave

CSNK2A1; MT: Delivery strategies; RNAi; delivery; fusogenic peptide; ovarian cancer; siRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Nucleic Acids Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google